高级搜索
原发性肝癌凝血及抗凝指标检测结果分析[J]. 肿瘤防治研究, 2002, 29(06): 471-472. DOI: 10.3971/j.issn.1000-8578.1292
引用本文: 原发性肝癌凝血及抗凝指标检测结果分析[J]. 肿瘤防治研究, 2002, 29(06): 471-472. DOI: 10.3971/j.issn.1000-8578.1292
Variation of coagulation and anticoagulation markers in patients with primary liver carcinoma[J]. Cancer Research on Prevention and Treatment, 2002, 29(06): 471-472. DOI: 10.3971/j.issn.1000-8578.1292
Citation: Variation of coagulation and anticoagulation markers in patients with primary liver carcinoma[J]. Cancer Research on Prevention and Treatment, 2002, 29(06): 471-472. DOI: 10.3971/j.issn.1000-8578.1292

原发性肝癌凝血及抗凝指标检测结果分析

Variation of coagulation and anticoagulation markers in patients with primary liver carcinoma

  • 摘要: 目的 探讨肝癌患者凝血及抗凝指标与肝癌病情及预后的关系。方法 对 4 9例肝癌患者 (其中 2 3例术后复查 )的部分凝血及抗凝指标进行检测。结果 肝癌合并肝硬化组PT、APTT、TT与正常组比较均显著延长 ;肝癌组术前FIB显著高于正常对照组, 肝癌并肝硬化组FIB则显著降低 ;肝癌患者TF活性均显著高于正常对照组 ;各组肝癌患者AT III活性均显著降低。结论 肝癌患者明显存在凝血及抗凝血激活状态, TF和AT III可作为肝癌诊断和判断预后的指标

     

    Abstract: Objective To investigate the variation coagulation and anticoagulation in patients with primary liver carcinoma(PLC) and their relationship with tumor incidence and development. Methods Partial coagulation and anticoagulation markers were measure in 49 patients with PLC. Results The length of PT, TT and APTT in group of PLC with cirrhosis were significantly longer than that of normal controls ( P <0.05~0.01).The decreased levels of FIB and AT-III were found in samples from 26 patients with cirrhosis...

     

/

返回文章
返回